SCHEMBL27057129

SCHEMBL27057129

COC(=O)CCOc1cc2nc(C)[nH]c(=O)c2cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ POLB P06746 2/20 0.49
▸ TSHR P16473 1/20 0.49
▸ TRPV1 Q8NER1 5/20 0.48
▸ ESR1 P03372 1/20 0.48
▸ KDM4E B2RXH2 5/20 0.48
▸ PDE3B Q13370 2/20 0.48
▸ PDE3A Q14432 2/20 0.48
▸ GAA P10253 2/20 0.48
▸ HTT P42858 1/20 0.47
▸ LMNA P02545 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ MAPT P10636 2/20 0.44
▸ TNF P01375 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ GLA P06280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29486866 0.92 MEN1 (0.47) MEN1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL29486836 0.92 MEN1 (0.47) MEN1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL27041289 0.92 MEN1 (0.47) MEN1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL27041273 0.92 MEN1 (0.47) MEN1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL29260841 0.84 TNF (0.56) MEN1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL30496286 0.84 TNF (0.56) MEN1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL6128121 0.82 KDM4E (0.62) MEN1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL27041207 0.81 MEN1 (0.47) MEN1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL27057151 0.80 TRPV1 (0.52) MEN1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL27057164 0.79 TRPV1 (0.48) MEN1KMT2ASMN1; SMN2POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025863-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2024-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025863-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS SOS1, SOS2, SOST MEN1 453/4885KMT2A 3570/4885SMN1; SMN2 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback